

PATIENT MEDICATION INFORMATION

READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE

PrEPKINLY™

Epcoritamab injection (solution for subcutaneous injection) / **Epcoritamab for injection** (concentrate for solution for subcutaneous injection)

Read this carefully before you start taking **EPKINLY** and each time you get a refill. This leaflet is a summary and will not tell you everything about this drug. Talk to your healthcare professional about your medical condition and treatment and ask if there is any new information about **EPKINLY**.

Serious Warnings and Precautions

- Fever (38°C or higher) and chills which may be symptoms of a serious side effect called cytokine release syndrome (CRS), which can be severe or fatal. Other symptoms of CRS may include difficulty in breathing, dizziness or feeling light-headed, feeling the need to throw up, headache, fast heartbeat, low blood pressure, feeling tired, vomiting, muscle pain and joint pain.
- Neurologic problems which may include symptoms like headache, confusion, difficulty with memory, difficulty speaking or slow speech, difficulty understanding speech, difficulty in writing, confused about time or surroundings, being less alert, or excessive sleepiness, and seizures (fits) which can be serious or life-threatening. Some of these may be signs of a serious immune reaction called 'immune effector cell associated neurotoxicity syndrome' (ICANS). These effects can occur days or weeks after you receive the injection, and may not be serious right away.

Your healthcare professional will monitor for signs and symptoms of CRS and neurological problems during treatment with EPKINLY. Call your doctor or get emergency help right away if you develop any of these signs and symptoms of CRS or neurologic problems at any time during your treatment with EPKINLY.

What is EPKINLY used for?

For the following indication(s) EPKINLY has been approved with conditions (NOC/c). This means it has passed Health Canada's review and can be bought and sold in Canada, but the manufacturer has agreed to complete more studies to make sure the drug works the way it should. For more information, talk to your healthcare professional.

- EPKINLY is used to treat some forms of large B-cell lymphomas – a cancer of blood cells (cancerous B cells), mostly in the lymph nodes. EPKINLY can be used in adults when the cancerous B cells have returned after other treatments or when other treatments did not work. It may be used if you are not able to receive or have previously received a treatment called CAR-T cell therapy.

What is a Notice of Compliance with Conditions (NOC/c)?

A Notice of Compliance with Conditions (NOC/c) is a type of approval to sell a drug in Canada.

Health Canada only gives an NOC/c to a drug that treats, prevents, or helps identify a serious or life-threatening illness. The drug must show promising proof that it works well, is of high quality, and is reasonably safe. Also, the drug must either respond to a serious medical need in Canada, or be much safer than existing treatments.

Drug makers must agree in writing to clearly state on the label that the drug was given an NOC/c, to complete more testing to make sure the drug works the way it should, to actively monitor the drug's performance after it has been sold, and to report their findings to Health Canada.

How does EPKINLY work?

EPKINLY is a cancer medicine (bispecific antibody) that binds to the surface of cancerous B cells and also to the surface of T cells (another type of white blood cell). This binding on two targets activates T cells, which causes them to multiply, and in turn helps kill the cancerous B cells.

What are the ingredients in EPKINLY?

Medicinal ingredients: epcoritamab

Non-medicinal ingredients: acetic acid, polysorbate 80, sodium acetate trihydrate, sorbitol, and water for injection

EPKINLY comes in the following dosage forms:

EPKINLY is available as single-dose vials: 4 mg in 0.8 mL sterile solution (5 mg/mL) or 48 mg in 0.8 mL sterile solution (60 mg/mL).

Do not use EPKINLY if:

- you are allergic to epcoritamab or any of the other ingredients of this medicine (listed in “What are the ingredients in EPKINLY?”). Talk to your doctor before you are given EPKINLY if you are not sure.

To help avoid side effects and ensure proper use, talk to your healthcare professional before you take EPKINLY. Talk about any health conditions or problems you may have, including if you:

- have or had problems with your nervous system – such as seizures
- have or had liver, kidney or heart problems
- have an infection
- are due to have a vaccine or you know you may need to have one in the near future
- are pregnant or plan to become pregnant

EPKINLY can cause serious side effects that can be severe or, life-threatening and can lead to death. These side effects include cytokine release syndrome (CRS) and immune effector cell associated neurotoxicity syndrome (ICANS).

Call your doctor or get emergency help right away if you get any of the following:

Cytokine Release Syndrome (CRS). Symptoms may include:

- fever (38°C or higher)
- low blood pressure
- chills
- fast heartbeat
- headache

Immune effector cell-associated neurotoxicity syndrome (ICANS). Effects on your nervous system which can occur days or weeks after you receive the injection and may initially be subtle. Some of these symptoms may be signs of a serious immune reaction called “immune effector cell associated neurotoxicity syndrome” (ICANS). Symptoms of ICANS may include:

- difficulty speaking or writing
- drowsiness
- confusion/disorientation
- muscle weakness
- seizures
- memory loss

If you notice any of these symptoms listed above, call your doctor or nurse right away.

Your doctor may give you medicine to treat your side effects. Your healthcare provider will check for these problems during treatment with EPKINLY.

Other warnings you should know about:

Pregnancy, contraception, breastfeeding and fertility

- Pregnancy must be ruled out before treatment. There is no information about the safety of EPKINLY in pregnant women. Tell your doctor immediately if you become pregnant. If you are a woman of child-bearing potential, use effective contraception during treatment with EPKINLY and for at least 4 months after the last dose of EPKINLY.
- Talk to your doctor or nurse about ways to avoid becoming pregnant.
- You must not breast-feed during treatment with EPKINLY and for 4 months after the last dose. EPKINLY may be passed into breast milk and could potentially harm the baby.
- The effects of EPKINLY on male and female fertility are not known.

Driving and using machines

- EPKINLY may affect your ability to drive, cycle, or use any tools or machines. If you have any symptoms that might make this difficult (such as fever, fast heartbeat, feeling dizzy or lightheaded, chills or shortness of breath, etc.) do not drive, cycle, or use any tools or machines until you feel better.

Tell your healthcare professional about all the medicines you take, including any drugs, vitamins, minerals, natural supplements or alternative medicines.

Interactions between epcoritamab and other drugs, vitamins, minerals, natural supplements or alternative medicines have not been established.

How to take EPKINLY:

Your doctor will give you EPKINLY as an injection under your skin (subcutaneous injection), on a dosing schedule, in 28 day cycles. You will be given EPKINLY according to the following schedule:

Cycle	Dosing Schedule
Cycle 1 to 3	Weekly
Cycles 4 to 9	Every other week
Cycles 10 and beyond	Every four weeks

You may be given other medicines before you are given EPKINLY. This is to help prevent reactions such as fever in Cycle 1 (and potentially future Cycles).

These other medicines may include:

- corticosteroids- such as prednisolone or equivalent
- an antihistamine – such as diphenhydramine
- acetaminophen

Usual dose:

Your first two doses are small doses given to you on Day 1 of Cycle 1 (0.16 mg) and Day 8 of Cycle 1 (0.8 mg) to manage side effects of this therapy.

The first full dose (48 mg) of EPKINLY will be given to you on Cycle 1 Day 15. For 24 hours following administration of the first full dose of 48 mg, you should remain within proximity of a healthcare facility. It is also possible that your healthcare professional decides to hospitalize you.

You will be given EPKINLY for as long as your doctor thinks you are benefitting from the treatment.

Your doctor may delay or completely stop your treatment with EPKINLY if you have certain side effects.

Overdose:

If you think you, or a person you are caring for, have taken too much EPKINLY, contact a healthcare professional, hospital emergency department, or regional poison control centre immediately, even if there are no symptoms.

Missed Dose:

If you miss an appointment to have EPKINLY administered, make another one straight away. For the treatment to be fully effective, it is very important not to miss a dose.

What are possible side effects from using EPKINLY?

These are not all the possible side effects you may have when taking EPKINLY. If you experience any side effects not listed here, tell your healthcare professional. You may only get one or some of these symptoms.

Very common (may affect more than 1 in 10 people):

- headache
- bacterial infection such as urinary tract infection
- decreased hunger
- viral infections such as lung infections (pneumonia)
- nausea
- diarrhea
- vomiting
- tiredness
- injection site reactions
- abdominal pain (pain in the belly area)
- back pain
- swelling
- constipation

Shown in blood tests:

- low levels of some white blood cells (neutropenia), which may lead to fever or symptoms of an infection such as chills, sore throat, shortness of breath, congestion, diarrhea
- low number of red blood cells, which can cause tiredness (anemia)
- low platelet count, which may make you more likely to bruise or bleed (thrombocytopenia)
- low levels of potassium in the blood

Common (may affect up to 1 in 10 people):

- pneumonia (lung infection)
- tumour lysis syndrome (a rapid breakdown of tumour cells resulting in chemical changes in the blood and damage to organs, including the kidneys, heart, and liver)
- difficulty sleeping
- extra fluid around the lungs that make it difficult to breathe (pleural effusion)
- increased heart rate
- cough
- difficulty breathing
- pain in bones and joints
- chills
- fungal infections (caused by a type of germ called a fungus)
- rash
- itching
- confusion

Shown in blood tests:

- low level of phosphates in the blood, potassium, magnesium or sodium
- increased blood level of liver proteins, which may show problems with the liver (ALT)

Tell your doctor straight away if you noticed any of the symptoms of the following serious side effects. You may only get one or some of these symptoms.

Serious side effects and what to do about them			
Symptom / effect	Talk to your healthcare professional		Stop taking drug and get immediate medical help
	Only if severe	In all cases	
VERY COMMON			
Cytokine release syndrome (CRS): fever, low blood pressure, chills, fast heartbeat, difficulty breathing, trouble breathing/low blood oxygen levels, headache		√	
COMMON			
Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS): difficulty speaking or writing, drowsiness, confusion/disorientation, muscle weakness, seizures, memory loss		√	
Serious infections: fever, chills, difficulty breathing, burning pain when passing urine, confusion		√	
Tumour Lysis Syndrome: kidney problems (weakness, shortness of breath, fatigue, feeling confused), heart problems (irregular heartbeat or fluttering of the heart or a faster or slower heartbeat), vomiting, diarrhea, tingling in the mouth, hands or feet, muscle cramp		√	

If you have a troublesome symptom or side effect that is not listed here or becomes bad enough to interfere with your daily activities, tell your healthcare professional.

Reporting Side Effects

You can report any suspected side effects associated with the use of health products to Health Canada by:

- Visiting the Web page on Adverse Reaction Reporting (<https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada.html>) for information on how to report online, by mail or by fax; or
- Calling toll-free at 1-866-234-2345.

NOTE: Contact your healthcare professional if you need information about how to manage your side effects. The Canada Vigilance Program does not provide medical advice.

Storage:

EPKINLY will be stored by the doctor, nurse, or pharmacist at the hospital or clinic. To correctly store EPKINLY:

Keep this medicine out of the sight and reach of children.

Store and transport refrigerated (2°C to 8°C).

Keep the vial in the original carton in order to protect from light.

Do not freeze. Do not shake.

If you want more information about EPKINLY:

- Talk to your healthcare professional
- Find the full product monograph that is prepared for healthcare professionals and includes this Patient Medication Information by visiting the Health Canada website: (<https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/drug-product-database.html>); the manufacturer's website (www.abbvie.ca), or by calling 1-888-704-8271.

This leaflet was prepared by AbbVie Corporation.

Last Revised: OCT 13, 2023

© 2023 AbbVie. All rights reserved.

EPKINLY™ is a trademark of AbbVie Biotechnology Ltd.

All trademarks, product names and company names or logos cited that are not AbbVie-owned or licensed trademarks within the content are used for identification purposes only and are the property of their respective owners. No right or license is being granted to AbbVie by implication or otherwise to use any third party owned trademarks.

Instructions For Use

EPKINLY 4 mg/0.8 mL

The following information is intended for healthcare professionals only:

EPKINLY (epcoritamab for injection) 4 mg/0.8 mL vial **must be diluted** using aseptic technique by a healthcare professional.

To prepare EPKINLY priming (0.16 mg) and intermediate (0.8 mg) doses, the following table outlines the materials needed for preparation of the priming and intermediate doses.

Materials needed	
Priming Dose	Intermediate Dose
4 mg/0.8 mL (5 mg/mL) EPKINLY vial with light blue cap	4 mg/0.8 mL (5 mg/mL) EPKINLY vial with light blue cap
0.9% Sodium Chloride Injection, USP	0.9% Sodium Chloride Injection, USP
Two empty sterile vials between 10 and 20 mL	One empty sterile vial between 10 and 20 mL
Recommended Syringe Sizes: <ul style="list-style-type: none">• Two 1 mL syringes• One 3 mL syringe• One 5 mL syringe• One 10 mL syringe	Recommended Syringe Sizes: <ul style="list-style-type: none">• Two 1 mL syringes• One 5 mL syringe

Priming Dose (0.16 mg) Preparation Instructions – Two Separate Dilution Steps Required:

Use a new, appropriately sized, syringe and needle for each transfer step.

- 1) Prepare EPKINLY vial
 - a. Retrieve one 4 mg/0.8 mL (5 mg/mL) EPKINLY (epcoritamab **for injection**) vial with the **light blue cap** from the refrigerator.
 - b. Allow the vial to come to room temperature for no more than 1 hour.
 - c. Gently swirl the EPKINLY vial.

DO NOT invert, vortex, or vigorously shake the vial.

- 2) Perform first dilution
 - a. Use an empty vial of an appropriate size. Label this vial as **“dilution A”**.
 - b. Using a 1 mL syringe, transfer **0.8 mL of EPKINLY** into vial labeled as **dilution A**.
 - c. Using a 5 mL syringe, transfer **4.2 mL of 0.9% Sodium Chloride Injection, USP** into vial labeled as **dilution A**.
 - d. Gently swirl the **dilution A** vial for 30 – 45 seconds.

At end of first dilution for priming dose, the concentration is 0.8 mg/mL.

- 3) Perform second dilution
 - a. Use the second empty vial of an appropriate size. Label this vial as **“dilution B”**.
 - b. Using a 3 mL syringe, transfer **2.0 mL of solution** from the vial labeled as **dilution A** into the **dilution B** vial. The **dilution A** vial is no longer needed.

- c. Using a 10 mL syringe, transfer **8.0 mL of 0.9% Sodium Chloride Injection, USP** into the **dilution B** vial.
- d. Gently swirl the **dilution B** vial for 30 – 45 seconds.

At end of second dilution for priming dose, the concentration is 0.16 mg/mL.

4) Withdraw dose

Using a 1 mL syringe for SC injection, withdraw **1 mL of the solution** from the **dilution B** vial.

5) Label syringe

Label the syringe 0.16 mg and include the time of day.

Discard the single-dose vial and any unused portions of EPKINLY in accordance with local requirements.

Intermediate Dose (0.8 mg) Preparation Instructions – One Dilution Step Required:

Use a new, appropriately sized, syringe and needle for each transfer step.

1) Prepare EPKINLY vial

- a. Retrieve one 4 mg/0.8 mL EPKINLY (epcoritamab **for injection**) vial with the **light blue** cap from the refrigerator.
- b. Allow the vial to come to room temperature for no more than 1 hour.
- c. Gently swirl the EPKINLY vial.

DO NOT invert, vortex, or vigorously shake the vial.

2) Perform dilution

- a. Use an empty vial of an appropriate size. Label this vial as **“dilution A”**.
- b. Transfer **0.8 mL of EPKINLY** into vial labeled as **dilution A**.
- c. Transfer **4.2 mL of 0.9% Sodium Chloride Injection, USP** into vial labeled as **dilution A**.
- d. Gently swirl the **dilution A** vial for 30 – 45 seconds.

At end of dilution for intermediate dose, the concentration is 0.8 mg/mL.

3) Withdraw dose

Using a 1 mL syringe for SC injection, withdraw **1 mL of the solution** from the **dilution A** vial.

4) Label syringe

Label the syringe 0.8 mg and include the time of day.

Discard the single-dose vial and any unused portions of EPKINLY in accordance with local requirements.

Instructions For Use

EPKINLY 48 mg/0.8 mL

The following information is intended for healthcare professionals only:

DO NOT dilute. EPKINLY (epcoritamab injection) 48 mg/0.8 mL (60 mg/mL) vial is ready to use.

1) Prepare EPKINLY vial

- a. Retrieve one 48 mg/0.8 mL (60 mg/mL) EPKINLY (epcoritamab **injection**) vial with the **orange** cap from the refrigerator.
- b. Allow the vial to come to room temperature for no more than 1 hour.**
- c. Gently swirl the EPKINLY vial.

DO NOT invert, vortex, or vigorously shake the vial.

2) Withdraw dose

Withdraw **0.8 mL of the EPKINLY** into a syringe for subcutaneous injection.

3) Label syringe

Label the syringe 48 mg and include the time of day.

Discard the single-dose vial and any unused portions of EPKINLY in accordance with local requirements.